Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca, Allergan Sign Another Antibiotic Pact

This article was originally published in Scrip

Executive Summary

Allergan Inc. and AstraZeneca plc will join forces to further develop and commercialize ATM-AVI, a fixed-dose antibiotic for the treatment of infections caused by metallo β-lactamase (MBL)-producing Gram-negative pathogens – bacteria for which there are few viable antibiotics.

You may also be interested in...



Keeping Track Of Review Designations: BTDs For X4, F2G, And BMS; Another QIDP For Allergan

The latest news about products accepted into US FDA expedited review programs.

AZ's Zavicefta Gains EU Positive Opinion For “Superbug” Infections

The CHMP followed recent EMA guidance to take a flexible approach to drugs against multi-resistant pathogens when recommending approval for AstraZeneca’s latest antibacterial Zavicefta.

Snapshot: April Highlights

A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC064365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel